IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael Yeadon

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

FILING DATE: Herewith

:Group Art Unit: To Be Assigned

TITLE: Pharmaceutical Combination

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: December 16,20

Robert T. Ronau

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.

Patent Department, Box 8260-1611

Eastern Point Road Groton, CT 06340

(860) 441-5910

EXPRESS MAIL NO. <u>EV 27 1824743</u>US

· · · · · · · · · · · · · · · · · · ·																
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 1 of 1							ATTY. DOCKET NO. PC22050B					SERIAL NO. To Be Assigned				
							APPLICANT Michael Yeadon									
							FILING DATE Herewith					GROUP To Be Assigned				
						U.S	. PATEN	IT DOC	UMENTS							
EXAMINER INITIAL				DOC	UMENT NUMB	ER		-	DATE	NAM	E	CLASS	SUBCLASS	FILING IF APPR	G DATE	
MITTAL								<u> </u>	<u> </u>	 						
	-													ļ		
	\vdash				-					-			 	\vdash		
								 					 	<u> </u>		
														<u> </u>		
														<u> </u>		
<u>.</u>														 		
												-t		 		
	<u>l </u>			<u> </u>		ORFI	GN PAT	FNT D	OCUMENTS				<u> </u>	<u></u>		
			DC	CUMENT NU					DATE	COUNTR	Y	CLASS	SUBCLASS	TRANS	SLATION	
	I'''' I			1			,	- ₁						YES	NO	
	wo	9	6	3	9	4	0	8	12 Dec 96	Internatio		C07D	471/14	↓	<u> </u>	
	wo	0	0	1	2	9	7	8	1 March 01 9 March 00	Internatio Internatio		A61K A61K	45/06 31/19	├─	⊢	
	"		"		+ +			 °	9 Walch 00	mternado	nai	AOIN	31/19	 	 	
				<u> </u>				†	 				1	 	\vdash	
			<u> </u>	<u> </u>												
	╁			-	-		<u> </u>	<u> </u>	<u> </u>				 	├ —	ـــ	
	1	·	ļ	+	+			_					_	┼—	\vdash	
			<u> </u>	·	 		<u> </u>	<u> </u>					1	 	\vdash	
														 		
			ļ		 		<u> </u>	ļ						└	<u> </u>	
	-			-			<u> </u>	_	<u> </u>					├─-	├	
				-				+	<u> </u>				1	 	 	
	<u> </u>		ОТН	IER DO	CUMENT	S (Inc	cluding A	Author.	Title, Date, Pe	ertinent Pa	aes. Et	c.)	<u> </u>	<u> </u>	l	
		Torph			ealth Persp						3 ,	/				
					Chem. 39,			44.047.4	005							
					acol. Bioche Pharmacol.				1995							
		Barne	tte et al.	,, J. Pham	nacol. Exp.	Ther.,	273, 674-6	679, 1995								
_	_ _				ysiol. Pharm narmacol. 33				97							
					m., 42, 108											
$ \top$		Burno	uf, et al.,	Current F	Pharm. Desi	gn, 20	02, 8, 125	5-1296								
						<u> </u>										
EXAMINE	R							DATE	CONSIDERED							
EXAMINER:	Initial if re	eference con	sidered, wr	nether or not o	citation is in con	formance	e with MPEP	609; Draw lir	ne through citation if n	ot in conformance	and not co	onsidered	Include convict	this form	with	
next commun	nication to	applicant.							d., Amanon II (II	comonitarios				101111		